Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus chemotherapy ± bevacizumab for recurrent/persistent/metastatic cervical cancer (Phase II, single-arm)
ChiCTR2500107989Phase 2Not yet recruiting
- Sponsor
- First Hospital of Nanping
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in cervical cancer (mCC) and Cervical Cancer (CC), sponsored by First Hospital of Nanping. Primary endpoint: Objective Response Rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
cervical cancer (mCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500107989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107989.